Western Alumni Magazine Feature

When Denise Bebenek (nee Day) graduated from Western University (class of 1983), she could not have known that her life’s work would help shape the future of paediatric brain tumour research around the world. Yet today, as Meagan Bebenek Foundation (MBF) marks its 25th anniversary, her vision stands as a powerful example of how one person’s determination can change the trajectory of medical discovery. 

​

Long before the phrase precision medicine became a buzzword in healthcare, Denise Bebenek was championing the very principles that now define it. 

​

Turning Personal Tragedy Into Global Impact 

​

Meagan Bebenek Foundation, the home of the HUG was established in memory of Denise’s daughter, Meagan, who passed away from a brain tumour. In the wake of unimaginable loss, Denise chose to focus on creating hope for other families facing similar diagnoses. 

​

At the time, paediatric brain tumour treatment relied heavily on generalized treatment protocols. Children with very different tumour types often received similar therapies, resulting in widely varying outcomes and severe long-term side effects.  

​

Denise recognized early what many in the medical field were only beginning to understand: every tumour is biologically unique. Unlocking its genetic and molecular profile could transform how children were treated. 

​

This insight would become the foundation of MBF’s mission. 

​

Investing in Precision Before It Had a Name 

​

In the early 2000s, the concept of tailoring treatment to the biology of an individual tumour was still emerging. Large funding agencies were hesitant to invest in this kind of exploratory research. 

​

Denise and the Foundation stepped in to fill that gap. 

​

Through early philanthropic seed funding, MBF helped launch pioneering research into tumour biology, molecular profiling, and genetic analysis at Toronto’s Hospital for Sick Children.  

 

The foundation helped support: 

• The development of tumour tissue banks 

• Early molecular and genetic analysis of paediatric brain tumours 

• Pilot studies identifying tumour subtypes and genetic mutations 

• Research infrastructure that enabled future international collaborations and clinical trials  

​

These investments were modest in scale but profound in impact. By funding early-stage ideas—often before traditional funding sources would support them—MBF allowed scientists to explore new approaches that would eventually reshape paediatric oncology. 

​

Today, these efforts form part of the global movement toward precision medicine. 

From Seed Funding to Breakthroughs 

​

Twenty-five years later, the impact of those early investments can be seen in real children and real families. 

​

Advances in molecular profiling now allow doctors to classify brain tumours more precisely and tailor treatments to the unique biology of each child’s disease. This approach improves survival while reducing the long-term effects of therapy on vision, growth, learning, and overall quality of life.  

​

One recent example is Massimo, who was diagnosed with an aggressive brain tumour as an infant. Thanks to insights from precision-based research, his treatment plan was tailored specifically to his tumour’s biology rather than relying on more toxic standard protocols. 

​

In April 2025, after six months of treatment, Massimo completed therapy—and his tumour was gone.  

​

Stories like Massimo’s are the living legacy of Denise Bebenek’s vision. 

​

The Power of Philanthropic Leadership 

Denise’s work illustrates a crucial truth in scientific discovery: breakthrough research often begins with bold early investment. 

Seed funding allows scientists to test new hypotheses, generate early data, and build the evidence needed to secure larger research grants. In many cases, these early philanthropic investments are the spark that leads to global advances in care. 

​

Meagan Bebenek Foundation has spent 25 years providing exactly that spark. 

​

A Legacy Still Growing 

​

As MBF celebrates its 25th anniversary, the foundation has launched the “25 in 25” campaign, aiming to fund 25 new seed research projects that could lead to the next generation of breakthroughs in paediatric brain tumour care.  

​

It is a fitting continuation of the work Denise began a quarter century ago. 

​

From Western alumna to global advocate for children with cancer, Denise Bebenek has demonstrated the extraordinary impact one person can have when compassion meets determination. 

​

In many ways, the precision medicine revolution now transforming paediatric cancer care traces part of its origins to a mother’s refusal to accept the status quo. 

​

And to the enduring belief that hope, when paired with action, can change the future.